Zenas BioPharma Quarterly Income Statement
NASDAQ: ZBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Zenas BioPharma revenue and earnings
In the quarter ended Jun 30, 2026, Zenas BioPharma generated $1.0 million in revenue, up 0.0% from the same quarter a year earlier. Zenas BioPharma reported a net loss of $111.5 million, compared with a loss of $52.2 million a year earlier. Operating margin was -10765.9%.
Diluted earnings per share came in at -$1.77.
Summary generated from market data by MetaCap's automated system. Methodology
Zenas BioPharma income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.00M | — | 0 | 0 | 0 | 10.00M | 5.00M | 0 | 0 | — | 0 | 50.00M |
| Revenue growth (YoY) | — | — | -100.00% | — | — | — | — | -100.00% | — | — | — | — |
| Operating Expenses | 108.66M | 77.35M | 237.98M | 52.58M | 55.16M | 47.33M | 60.62M | 40.98M | 39.70M | 27.58M | 24.78M | 14.38M |
| Research & Development | 62.91M | 60.44M | 55.72M | 34.40M | 43.03M | 34.91M | 49.16M | 33.53M | 33.81M | 22.64M | 20.42M | 9.35M |
| Operating Income | -107.66M | -77.35M | -237.98M | -52.58M | -55.16M | -37.33M | -55.62M | -40.98M | -39.70M | -27.58M | -24.78M | 35.62M |
| Interest Expense | 1.72M | 368.00K | — | — | — | — | — | — | — | — | — | — |
| Other Income (Expense) | -3.68M | -3.64M | -2.35M | 1.08M | 2.96M | 3.55M | 3.45M | 2.38M | 1.73M | -222.00K | 493.00K | -16.00K |
| Pretax Income | -111.34M | -80.99M | -240.34M | -51.50M | -52.20M | -33.78M | -52.17M | -38.61M | -37.98M | -27.80M | — | — |
| Income Tax | 114.00K | — | 106.00K | 0 | 20.00K | -205.00K | — | — | — | — | — | — |
| Net Income | -111.46M | -80.99M | -240.44M | -51.50M | -52.22M | -33.57M | -52.60M | -38.61M | -37.98M | -27.80M | -24.59M | 35.61M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | -208.42% | — | — | — | — |
| EPS (Basic) | -1.77 | -1.46 | -5.17 | -1.22 | -1.25 | -0.80 | 35.25 | -5.02 | -24.23 | -17.89 | — | 2.42 |
| EPS (Diluted) | -1.77 | -1.46 | -5.17 | -1.22 | -1.25 | -0.80 | 35.25 | -5.02 | -24.23 | -17.89 | — | 1.96 |
| Shares Outstanding (Basic) | 63.11M | 55.62M | — | 42.16M | 41.87M | 41.80M | — | 7.70M | 1.57M | 1.55M | — | 1.54M |
| Shares Outstanding (Diluted) | 63.11M | 55.62M | — | 42.16M | 41.87M | 41.80M | — | 7.70M | 1.57M | 1.55M | — | 1.90M |
| EBITDA | -107.66M | -77.34M | -237.97M | -52.57M | -55.15M | -37.31M | -55.59M | -40.95M | -39.67M | -27.55M | -24.75M | — |
| Operating Margin | -10765.90% | — | — | — | — | -373.30% | -1112.46% | — | — | — | — | 71.25% |
| Net Margin | -11145.60% | — | — | — | — | -335.73% | -1052.08% | — | — | — | — | 71.22% |
This table shows 12 quarterly periods of Zenas BioPharma's income statement, from Q2 2026 back to Q3 2023, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow ZBIO's reporting calendar. What is a income statement?